Dr. Maura Campbell is President and CEO of the Ontario Bioscience Innovation Organization (OBIO®), a not-for-profit organization dedicated to advancing health technology innovation and commercialization. Dr. Campbell has more than 30 years of leadership experience in managing successful companies in all key sectors of biotech, including private and public companies, universities and research institutes, and government-funded public sector research organizations.
With expertise in technology transfer and commercialization of intellectual property, Dr. Campbell has held various roles in senior management, most recently as the Vice-President of Intellectual Property and Contracts for Turnstone Biologics. At Turnstone, she played a crucial role in the company’s seed and Series A, B, C, and D financing, in addition to executing two large pharma-licensing deals, raising over US $370 million since the company’s inception in 2015. Dr. Campbell previously served as Director, Intellectual Property at VBI Vaccines. Among the various roles she held in her career are Senior Research Program Manager, and Manager of Technology Transfer & Commercialization at the Ottawa Hospital Research Institute, Director of Intellectual Property for PainCeptor Pharma Corporation, and Manager of Technology Transfer at the Institute for Robotics and Intelligent Systems National Centre of Excellence. 
Dr. Campbell holds a Ph.D. in biochemistry from the University of Ottawa, and an M.Sc. and a B.Sc. in biochemistry from Queen’s University in Kingston. Most recently, Dr. Campbell accepted an appointment to the Ontario Life Sciences Council, joining eleven other industry experts to support a plan to make Ontario a top hub for innovation growth and life sciences investment.